NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers” o ...

Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

The Nutrition Center warns people who want to lose weight not to take medication too lightly. “It may seem easy, but do not ...